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Background: Certain S100 proteins induce 
cell migration and metastasis but the 
molecular mechanism is not clear 
Results: S100P preferentially binds and 
disperses NMIIA fibres and subsequently 
affects focal adhesion sites (FAS) and cell 
adhesion 
Conclusion: S100P over-expression reduces 
the assembly of NMIIA-FAS to enhance cell 
migration by reducing anchorage forces 
Significance: The mechanism of the primary 
step of S100P-induced metastasis has been 
elucidated. 
 
SUMMARY  
     S100 proteins promote cancer cell 
migration and metastasis.  To investigate their 
roles in the process of migration we have 
constructed inducible systems for S100P in rat 
mammary and human HeLa cells that show a 
linear relationship between its intracellular 
levels and cell migration. S100P, like S100A4, 
differentially interacts with the isoforms of 
nonmuscle myosin II (NMIIA, Kd = 0.5 μM ; 
IIB, Kd = 8 μM; IIC, Kd = 1.0 μM). 
Accordingly, S100P dissociates NMIIA and 
IIC filaments but not IIB in vitro. NMIIA 
knockdown increases migration in non-
induced cells and there is no further increase 
upon induction of S100P, whereas NMIIB 
knockdown reduces cell migration whether or 
not S100P is induced. NMIIC knockdown does 
not affect S100P-enhanced cell migration.  
Further study shows that NMIIA physically 
interacts with S100P in living cells. In the 
cytoplasm, S100P occurs in discrete nodules 
along NMIIA-containing filaments.  Induction 
of S100P causes more peripheral distribution 
of NMIIA filaments.  This change is paralleled 
by a significant drop in vinculin-containing, 
actin-terminating focal adhesion sites (FAS) 
per cell. The induction of S100P, consequently, 
causes significant reduction in cellular 
adhesion. Addition of a focal adhesion kinase 
(FAK) inhibitor reduces disassembly of FAS 
and thereby suppresses S100P-enhanced cell 
migration. In conclusion, this work has 
demonstrated a mechanism whereby the 
S100P-induced dissociation of NMIIA 
filaments leads to a weakening of FAS, 
reduced cell adhesion and enhanced cell 
migration, the first major step in the 
metastatic cascade. 
S100 proteins, such as S100B, S100A2, 
S100A4, S100A6, and S100P are upregulated in 
the primary  tumors of many cancers, including 
those of the breast, brain, lung, pancreas, 
prostate, and colon (1-3). Moreover their 
overexpression in the primary tumor is often 
associated with poor patient prognosis and is 
believed to be due to their ability to induce cell 
migration and metastasis (4-10). Artificial 
transfection and thereby upregulation of certain 
S100 proteins can modulate the cytoskeleton and 
increase cell migration in many diverse systems 
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in vitro (11-13).  The major molecules of the 
acto-myosin cytoskeleton in cancer cells are the 
isoforms of non-muscle myosin IIs (NMIIs), 
NMIIA, IIB and IIC. NMIIA is associated with 
organisation of stress fibres, focal adhesion sites 
(FAS) and tissue architecture (14).  NMIIB is 
involved in stabilising normal cell polarity (15) 
and is essential for heart and brain development 
(16,17). NMIIC is a recently discovered isoform  
whose function is poorly understood (18), but it 
may share properties with NMIIA and IIB  (19).  
One S100 protein, S100A4, has been shown 
to interact with NMIIA (12,20). This interaction 
directly inhibits the formation of filaments of 
NMIIA in vitro (11) and increases cell migration 
in vivo (21). In contrast, the interaction of 
S100A4 with NMIIB is much weaker (22). In 
different cellular systems, when expression of 
NMIIA is knocked down, cell migration is 
increased, but when NMIIB is knocked down, 
cell migration is reduced (23). These 
observations suggest that S100A4 and perhaps 
other S100 proteins may interact differentially 
and regulate these different NMII isoforms to 
achieve an overall increase in cell migration, but 
how the overall increase is achieved is unknown. 
To test how this is brought about, S100P has 
been used as a representative of the S100 
proteins, because its metastasis-promoting 
property has been well characterised in vivo (7) 
and S100P-inducible cell lines have been 
successfully established from a rat breast tumor 
cell line and from HeLa ovarian cancer cells. We 
now show that S100P also binds preferentially to 
NMIIA, partially dissociates its filaments and 
causes their redistribution, and that these changes 
are companied by a redistribution of FAS, from 
the central area to the cellular periphery. The 
number of FAS per cell is also significantly 
decreased. Consequently cell adhesion is reduced 
and cell migration is enhanced.  These changes 
suggest that the weakening of the anchorage 
forces generated through NMIIA to FAS will 
allow intact NMIIB filaments to drive cell 
migration.  
 
EXPERIMENTAL PROCEDURES 
Cell culture- The Rama 37 cells, a non-
metastatic benign rat mammary tumor cell line 
expressing undetectable levels of S100P, S100P 
cDNA transfected cell lines (Rama 37-S100P-1, 
2; Rama 37 pool-1, 2) and control vector alone 
transfected cell line (Rama 37-vector), were 
established and cultured as described previously 
(7). Human cancer cell lines, HeLa, MCF-7 and 
MDA-MB-231, cells were cultured routinely 
(24). 
 Establishment of doxycycline inducible cell 
system-  The tetracycline inducible system (gifted 
by Dr. Adam West, NIH, USA) contains two 
plasmids, pBTE to express a regulatory element 
rtTA2(S)-M2 (25), and pTRE-ins to express 
target protein. Two inducible clones derived from 
Rama 37 cells were termed Rama 37-T25 and 
T28, while two inducible clones derived from 
HeLa cells were termed HeLa-A3 and A19.  The 
concentration of doxycycline and induction 
period was optimised and 1 μg/ml of doxycycline 
for 24 h was used in all the inductions 
(Supplemental Fig.1).  
Measurement of cell migration- Migration of 
cell lines was measured 24 h after the cells were 
seeded in Boyden Chambers using 6.5 mm 
diameter polycarbonate membrane inserts 
containing 8 µm pores (Corning Costar, Acton, 
USA)(26),  as described previously (27) . The 
inducing agent, doxycycline, inhibitors, or 
blocking peptide and antibodies were added to 
both upper and lower compartments of the 
Boyden Chambers. To standardise results 
between different experiments, usually the cell 
line controls were set to 100% migration and 
changes relative to this value were shown in most 
Figs.   
 SiRNA transfections- Two siRNA sequences 
used for targeted silencing of human S100P and 
four siRNA sequences for each human NMII 
isoforms, vinculin, Rac1 and RhoA were 
designed and synthesized by Qiagen (Crawley, 
UK) (Supplemental Table1).   S100P-expressing 
MCF-7 and HeLa/HeLa-A3/HeLa-A19 cell lines 
were used for testing S100P siRNAs,NMII 
siRNAs, vinculin, Rac1 and RhoA siRNAs, 
respectively. RNAi Starter kit (301799), 
including RNAiFect, negative control siRNA, 
were from Qiagen.  The siRNA transfection 
procedure followed Qiagen’s instructions.   At 48 
h after transfection, the levels of S100P, NMIIA 
IIB (Supplemental Figs. 2A&B), vinculin, Rac1 
and RhoA  were measured using Western blotting 
and the levels of NMIIC mRNA (Supplemental 
Fig. 2C) by semi-quantitative RT-PCR, because 
there was no satisfactory antibody for NMIIC. 
Semi-quantitative RT-PCR- Total RNA was 
extracted using Trizol reagent (Invitrogen, 
Paisley, UK). Reverse transcription was carried 
out using a Cloned AMV First-Strand synthesis 
Kit (Invitrogen).  The resultant cDNA was used 
as template for the amplification of actin (18 
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cycle) and NMIIC (25 cycle) by PCR using 
primers listed in Supplemental Table 2. 
Recombinant Proteins- The recombinant 
human S100P protein was purified as described 
previously (28,29). The rC-NMIIA (C-terminal 
149aa), IIB (C-terminal  204 aa) and IIC (C-
terminal  178aa) were produced using the same 
method as used previously for rC-NMIIA (30) 
with primers listed in Supplemental Table 2. The 
deletion mutants of rC-NMIIA, M1, M2, M3, 
M4, M5, were produced by the PCR extension 
method (31,32) .  
Western blotting- S100P was detected using 
mouse anti-S100P mAb (1:50 dilution) (BD 
Science, San Jose, USA), which showed no cross-
reaction with S100A1, S100A2 or S100A4 (7). 
FAK was isolated using anti-FAK conjugated 
agarose (Millipore, Billerrica, USA) from 1 mg 
protein prior to SDS-PAGE.  NMIIA, IIB, FAK, 
phospho-FAK (pFAK) and actin were detected 
using rabbit polyclonal anti-NMIIA, IIB 
(Covance, Princeton, USA),  mAb-FAK and 
polyclonal anti-pFAK Y(397) (Upstate, New 
York, USA).   
Gel overlay assay- Briefly, equal amounts of  
proteins (3 μg) were subjected to SDS-PAGE 
(33). One gel was stained with Coomassie 
brilliant blue to check equal loading and the other 
two gels were electro-blotted onto PVDF 
membranes, which were then incubated at 4oC 
overnight with S100A4 (3 µg/ml) or S100P (3 
µg/ml) in Overlay Buffer (12).  The rest of the 
procedures were the same as those of 
conventional Western blotting.  
 Binding assays- Binding reactions were 
carried out in an IAsys two-channel resonant 
mirror biosensor (Affinity Sensors, Saxon Hill, 
Cambridge, U. K.), as described previously (34); 
the rC-NMIIA, IIB or IIC protein fragment was 
immobilized on aminosilane surfaces using BS3 
(Perbio, Chester, UK). The equilibrium 
dissociation constant (Kd) was  calculated both 
from the association and dissociation rate 
constants, and from the extent of binding at or 
near equilibrium (34).  
Sedimentation assay- Briefly, 5 µM of rC-
NMIIA, IIB or IIC was incubated at 4oC 
overnight in Bundling Buffer (10 mM imidazole-
HCl (pH 7.5), 100 mM NaCl, and 2.5 mM 
MgCl2)(35).   To test the effect of S100P on rC-
NMII sedimentation, 0- 10 µM of S100P was pre-
incubated with rC-NMIIA, IIB or IIC with 0.5 
mM CaCl2 at room temperature for 40 min. 
Bundling Buffer was then added and NaCl and 
MgCl2 adjusted to 100 mM and 2.5 mM, 
respectively.  Twenty µl of mixture was removed 
and kept at -20oC as a control, and the remainder 
was incubated overnight at 4oC. After 
centrifugation at 13,600 g for 30 min at 4oC, 20 
µl of the supernatant was subjected to SDS-
PAGE together with control. Anti-His-tag 
antibody (Sigma) was used to detect rC-NMIIA, 
IIB and IIC by Western blotting. To test if S100P 
disassociates the preformed NMII filaments, the 
rC-NMIIA, IIB and IIC were incubated in 
Bundling Buffer for 48 h. After centrifugation, 
pellets were resuspended in Bundling Buffer 
containing 0, 3 µM S100P. After 40 min 
incubation, the mixtures were centrifuged and 
resultant supernatants were analysed. 
  Immunofluorescent staining- Culture of the 
human breast cancer cell line MCF-7 and dual 
immunofluorescent staining were carried out as 
described before (24).The cells were grown on 
the untreated glass surface of 8-well chamber 
slides (BD Science). S100P was detected with the 
MAb (BD Science) at 1:50 dilution and 
visualised with FITC-conjugated goat anti-mouse 
antibody (Sigma). NMIIA and IIB were detected 
with rabbit anti-NMIIA and IIB IgGs (Covance, 
Princeton, USA) at 1:5000 dilution and visualised 
with Texas Red-conjugated goat anti-rabbit 
antibody (Molecular Probes, Eugene, USA).  
Actin filaments were visualized with Atto 647N-
Phalloidin (Sigma). FAS were detected with mAb 
(Sigma) at 1:2000 dilution and visualized as for 
S100P.  Images were recorded using a Zeiss LSM 
510 confocal microscope. 
Fluorescent lifetime imaging- For fluorescent 
resonance energy transfer (FRET) analysis, the 
expression plasmids, pECFP-S100P and 
pNMIIA-EYFP were constructed  by inserting  
S100P and NMIIA coding sequences into 
pECFP-C1 vector (Clontech, Palo Alto, CA) and 
pEYFP-N1 vector (Clontech) at the HindIII and 
BamHI sites, respectively. The correct coding 
sequences for the two fusion proteins, ECFP-
S100P and NMIIA-EYFP were confirmed by 
DNA sequencing. The pECFP-S100P and the 
pNMIIA-EYFP/pEYFP-C1 expression vectors 
were then co-transfected into HeLa cells. The 
time-resolved fluorescence decay maps were 
collected pixel-by-pixel from the HeLa cells co-
expressing ECFP-S100P and NMIIA-EYFP 
fusion proteins or from the HeLa cells co-
expressing ECFP-S100P and EYFP by a scanning 
confocal microscope using time-correlated single 
photon counting (TCSPC) (36) fluorescence 
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lifetime imaging module (SPC-730) (Becker 
&Hickl, Berlin, Germany) and a photomultiplier 
tube (PMH-100-1, Hamamatsu, Bridgewater, 
USA). Fluorescence lifetime imaging microscopy 
(FLIM) images were analyzed using SPCImage 
2.0 (Becker & Hickl). The methods for 
calculation of fluorescence lifetime and the 
distance between donor and acceptor as well as 
the statistical analysis are fully described 
elsewhere (37). 
Timelapse confocal microscopy- GFP-NMIIA 
expression plasmid (full length) was obtained 
from Addgene, Cambridge, USA. The HeLa-A3 
was grown on glass bottom dishes (Matsunami 
Glass, Tokyo, Japan) and transfected with the 
plasmid using Lipofectamine (Invitrogen). 
Doxycycline (1 µg/ml) was added to the cell 
culture 16 h after transfection. Images of 
transfected cells were recorded in a Zeiss LSM 
510 confocal microscope for a further 24 h.  
Triton-insoluble NMIIA detection- Equal 
number of HeLa and HeLa-A19 cells were 
cultured in the presence or absence of 
doxycycline for 24 h and washed with ice cold 
PBS. The cells were then incubated with ice cold 
cytoskeletal lysis buffer (40 mM sodium 
pyrophosphate, 20 mM potassium phosphate, 3 
mM EGTA (pH 7.4) and 1% Triton X-100 for 5 
min on ice. The buffer was then removed to a 
fresh tube and 20 µl was taken for soluble actin 
detection.  The material remaining on the dish 
after two washes with the buffer was considered 
as the detergent-insoluble cytoskeletal fraction 
and harvested by adding 2xSDS gel loading 
buffer. The insoluble NMIIA and soluble actin 
(as a loading control) were detected by Western 
blotting.  
Peptide synthesis and transfer – The S100P 
binding domain of NMIIA fused with TAT-HA2 
(38) was synthesized by GeneCust Europe, 
(Luxembourg). TAT-HA2 was used as control 
peptide. HeLa and HeLa-A19 cells were 
incubated with 5 µM peptides for 24 h. Cell 
migration assay was set up in the presence or 
absence of doxycycline.  
Cell adhesion assay – A modified attachment 
assay (39) was carried out. HeLa and HeLa-A19 
cells were induced with 1 µg/ml doxycycline for 
24 h. The cells were then detached by EDTA 
which was neutralised by culture medium, 
washed with PBS and resuspended to 4 x 105/ml 
in basal medium without serum, 50 μl cells were 
seeded in each well of 96-well microtiter plate 
(Costar, Cambridge, USA). After incubation in 
CO2
 
incubator at 37 oC for 5, 30, 60 or 90 min, the 
plate was shaken at 2000 rpm for 10-15 seconds 
and washed with PBS for 3 times. The remaining 
cells were fixed with 5% (w/v) glutaradehyde. 
After washing, the cells were stained with crystal 
violet for 10 min. After washing with water 5 
times, the plate was dried and 100 µl 10% (v/v) 
acetic acid was added. After 30 min incubation, 
the absorption was recorded at 570 nm. The cell 
adhesion assay kit was purchased from Millipore 
and used according to the supplier’s instructions.  
 
 
RESULTS 
Regulation of the levels of intracellular S100P 
affects cell migration.  When the rat mammary 37 
(Rama 37) cells were transfected with an 
expression vector for S100P,  the resultant 
transfectants, R37-S100P-1 and R37-S100P-2, 
and two pooled clones, pool-1 and, pool-2 (7), 
expressed 6-14 fold of S100P mRNA and 5-12 
fold of S100P protein over the pooled empty 
vector-transfected Rama 37 cells (R37-vector), 
causing an increase in  cell migration of 30-70% 
(Figs. 1A&B) (ANOVA test, P<0.01).  To down 
regulate the levels of S100P, two specific small 
interference RNAs (siRNAs) to the mRNA for 
S100P were synthesised and transfected into 
MCF-7 cells, a human breast cancer cell line that 
expressed high levels of S100P. The siRNA 
duplex 1 and 2 separately reduced the levels of 
S100P in MCF-7 cells to 10% and 80%, 
respectively and led to a reduction in cell 
migration of about 45% and 75%, respectively 
(P=0.004 and P=0.2) (Figs. 1C&D). To 
upregulate the levels of S100P, the doxycycline-
inducible cell lines, Rama 37-T25, T28 and 
HeLa-A3 and A19 were constructed from rat 
mammary benign and human malignant ovarian 
cells. After addition of 1 µg/ml doxycycline for 
24 h, the level of S100P was significantly 
increased by 5-10 fold (P≤0.001) and that of cell 
migration by 2-3 fold, respectively (P≤0.008) 
(Figs. 1E&F).  Levels of S100P and migration of 
Rama 37 and HeLa showed no significant 
differences with or without inducing agent 
(P≥0.30; Figs. 1E&F).  There was a significant 
positive correlation between the levels of S100P 
and cell migration (Supplemental Fig. 3). 
Although there is no secretion signalling 
peptide in any of the S100 proteins, it is thought 
that the S100 proteins can be secreted and may 
function at low concentrations of around 100 nM 
(1 µg/ml)(40,41) by activating the receptor for 
advanced  glycation end-products (RAGE) on the 
cell surface (42,43). However, S100P was not 
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detectable in the conditioned medium of 
doxycycline-induced or non-induced R37-T25 
and HeLa-A3 cells (Fig. 1G). When 100 nM 
human recombinant S100P (rhS100P) was added 
to Rama 37-T25 or to HeLa-A3 cells (Fig. 1H), it 
produced no significant increase in cell migration 
(P≥0.23), although it significantly increased cell 
invasion (Du, Wang and Rudland unpublished 
data). Increasing the dose of rhS100P up to 1 µM 
did not achieve significant increase of cell 
migration (data not shown). Moreover, the RAGE 
neutralising antibody or blocking peptide (8,43) 
did not significantly inhibit cell migration 
enhanced by doxycycline-induced S100P (Fig. 
1H)(P≥0.09). These data suggest that the 
upregulation of intracellular S100P, but not the 
secreted S100P, is the primary cause of S100P-
enhanced cell migration at least in those cell lines 
tested.  
Preferential interaction of S100P with NMIIs 
interferes with their corresponding filament 
formation. The recombinant C-terminal 
fragments of NMIIA, IIB and IIC (rC-NMIIA, B, 
C) were separately immobilized onto a biosensor 
and the extent of binding of different 
concentrations of S100P was measured in a buffer 
containing 0.5 mM Ca2+. The binding 
characterized by fast association kinetics was 
always homogeneous and there was no evidence 
for more than one binding site for S100P. The 
equilibrium dissociation constants (Kd) for rC-
NMIIA, IIB or IIC calculated from these kinetic 
parameters were: 430±210; 7,800±4,200; and 
1,000±530 nM, respectively, very similar to the 
Kd’s calculated from the extent of binding 
observed at equilibrium of: 500±200; 
8,400±1,200; and 490±100 nM, respectively 
(Table 1). Therefore, the binding affinity of 
S100P with rC-NMIIA is similar to that with rC-
NMIIC and is 10-20 fold higher than that with 
rC-NMIIB.  
Binding of S100A4 has been mapped to amino 
acids 1909-1937 of NMIIA (20). Since S100P has 
a similar structure (44,45), the deletion mutant 
polypeptides of NMIIA (M1-M5) used for 
mapping S100A4 binding sites (20) were 
employed for S100P (Figs. 2A-C). Since mutant 
M1 failed to bind, but mutants M2 and M3 did so 
to S100P, the region from amino acid 1909 to 
1937 of the rC-NMIIA is confirmed to be a major 
sequence for S100P and S100A4 binding (Figs. 
2A- C). The additional binding to M3 over M2 
(Figs. 2B, C) suggests partial overlap of this 
binding site with the filament assembly domain 
which plays an important role in regulating 
NMIIA filament formation (Fig. 2A)(22,46).  
When S100P was pre-incubated with rC-
NMIIA or IIC, formation of their filaments was 
inhibited. Thus when mixtures that contained rC-
NMIIA and S100P were centrifuged, the amount 
of soluble rC-NMIIA retained in the supernatant 
was significantly increased by about 2 fold for 
0.3 µM to 6 fold for 10 µM S100P (ANOVA test, 
P<0.01) (Figs. 2D&E).  In contrast, prior 
incubation of S100P with rC-NMIIB showed no 
significant change (P>0.05).When S100P was 
pre-incubated with NMIIC, the amount of soluble 
form increased by 6-fold for 3 µM and 10 fold for 
10 µM S100P; hence the formation of NMIIC 
filaments was also significantly inhibited by 
S100P (P<0.01) (Figs. 2D&E).  When 3 µM 
S100P was added to preformed  filaments of 
specific NMII isoforms, S100P  significantly 
increased  the amount of soluble forms of NMIIA 
and IIC  by 6 and 2.7 fold on average, 
respectively (Student’s t test, P≤0.007),  but not 
those of  NMIIB (P=0.25)(Figs. 2F&G). This 
result shows that S100P can partially dissociate 
preformed NMIIA and IIC filaments, but not 
those of NMIIB.  
Knocking down NMII isoforms affects S100P-
induced cell migration. When expression of 
NMIIA was knocked down by over 90% using 
specific siRNA in HeLa-A3 cells (Supplemental 
Fig. 2A), cell migration was significantly 
increased by 64-123% (P<0.025)(Fig. 3A, non-
induced), while knocking down NMIIB by 80-
90% (Supplemental Fig. 2B) significantly 
reduced cell migration to 31-60% of its original 
value (P≤0.02)(Fig. 3B, non-induced). When 
expression of NMIIC was knocked down by 70% 
(Supplemental Fig. 2C), cell migration did not 
change significantly (P≥0.12)(Fig. 3C, non-
induced).   When S100P was induced prior to 
NMIIA knockdown, the subsequent knockdown 
of NMIIA failed to increase significantly cell 
migration any further (P≥0.24)(Fig. 3A, induced) 
and vice versa (P≥0.21)(Fig. 3D). When the 
expression of S100P was induced and then that of 
NMIIB was knocked down, cell migration was 
decreased by 47- 83% (Fig. 3B, induced) (P=0.02 
and P=0.08). When NMIIB was knocked down 
and S100P was then subsequently induced, there 
was no significant increase in cell migration 
(P≥0.12)(Fig. 3E), suggesting that NMIIB could 
be the major driver of cell migration. Either when 
S100P was induced before (Fig. 3C, induced) or 
after (Fig. 3F) NMIIC was knocked down, cell 
migration was significantly increased by 55-
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121% (Student’s t test, P≤0.033), which is similar 
to cells transfected with control siRNA, 
suggesting that NMIIC fails to play a major role 
in regulating S100P-enhanced cell migration. 
These data strongly indicate that S100P increases 
cell migration mainly through its effect on 
NMIIA.   
Co-localisation and physical interaction of 
S100P with NMIIA in living cells. In MCF-7 
cells, S100P protein was distributed both in the 
nucleus and in the cytoplasm. Cytosolic S100P 
was more concentrated in the perinuclear region 
(Fig. 4A panels A&D), the same as that in green 
fluorescent protein (GFP)-S100P transfected cells 
(Supplemental Fig. 4). The cytosolic S100P 
formed scattered focal densities (Fig. 4A panels 
A&D). The NMIIA protein occurred in cytosolic 
filaments (Fig. 4A panels B&E), and also formed 
nodules along the filaments. Some of these 
nodules co-localised with the majority of S100P-
containing focal densities (Fig. 4A panels C&F). 
To investigate if S100P physically interacts with 
NMIIA in mammalian cells, the plasmid 
expressing enhanced cyan fluorescent protein 
(ECFP)-S100P fusion protein and the plasmid 
expressing NMIIA-EYFP (enhanced yellow 
fluorescent protein) or EYFP alone were co-
transfected into HeLa cells. The fluorescent 
lifetime of ECFP-S100P was measured both from 
cells co-expressing ECFP-S100P and NMIIA-
EYFP (1.12±0.14 ns, mean±SD from 7 different 
cells in two independent transfections) (Fig. 4B 
panel A), and cells co-expressing ECFP-S100P 
and EYFP (2.38±0.07 ns, mean±SD from 5 
different cells in two independent transfections) 
(Fig. 4B panel B). A significant reduction 
(Student’s t test, P< 0.01) in the mean fluorescent 
lifetime of ECFP-S100P was observed in the cells 
co-expressing NMIIA-EYFP compared to that of 
cells co-expressing EYFP (Fig. 4B panel C).  The 
reduction in mean fluorescence lifetime resulted 
from the transfer of the energy from the optically 
excited ECFP-S100P to NMIIA-EYFP but not to 
the EYFP. This indicates that the S100P and 
NMIIA were in physical contact, i.e. < 5 nm apart 
(47,48).   These data confirmed that the in vitro 
interactions between S100P and NMII isoforms 
also occur in vivo. 
S100P induces reorganisation and reduces the 
total amount of NMIIA filaments in living cells. 
GFP-tagged full length NMIIA (Fig. 5A) was 
expressed in HeLa-A3 and A19 cells by transient 
transfection.  Doxycycline was added at 16 h 
after transfection. At that time, NMIIA filaments 
were visible and distributed uniformly in the 
majority of GFP-fluorescing cells, with only 7-
10% showing a peripheral distribution 
(Supplemental Table 3). About 5% of fluorescing 
cells had no obvious filaments or only aggregated 
GFP-tagged NMIIA. Only cells with clear 
filaments were chosen for the time lapse confocal 
microscopy. About 60 cells in 24 locations were 
monitored for over 24 h in each of 3 independent 
experiments. About 20-30% of monitored cells 
either died or were lost in the field of view before 
24 h and were censored. About 50-60% of the 
remainder with GFP-IIA fluorescent filaments 
underwent a significant (Student’s t test, 
P≤0.039) redistribution from an even to a more 
peripheral location upon induction of S100P (Fig. 
5A)(Supplemental Table 3), the remaining 30-
40% did not show obvious change in distribution 
of filaments. In contrast, when S100P was not 
induced in HeLa-A3, A19 cells or HeLa cells 
were treated with doxycycline, cells with 
fluorescent NMIIA containing filaments 
exhibited a similar low level of about 10% of 
peripherally distributed filaments (Supplemental 
Table 3).  The amount of Triton-insoluble NMIIA 
was also significantly reduced  by about 30-40% 
in HeLa-A19 cells 24 h after adding 1 µg/ml 
doxycycline compared to that without 
doxycycline (Figs. 5B&C)(P<0.05) but no 
significant difference between HeLa cells with or 
without doxycycline treatment.  These data 
indicate that S100P-induced redistribution of 
NMIIA is companied by the dissociation of 
NMIIA filaments.  
NMIIA peptide blocks NMIIA-S100P 
interaction and S100P-enhanced cell migration. 
The S100P binding domain of NMIIA (Fig. 6A) 
was fused with TAT-HA2 (38). TAT is the HIV 
Tat protein transduction domain and is used for 
delivery of peptides into cells (Fig. 6A) (49).  
Since TAT-delivered peptides are often trapped 
in macropinosomes, HA2, the N-terminal of the 
influenza virus hemagglutinin protein, a well 
characterized, pH-sensitive peptide that 
destabilizes lipid membranes at low pH (50), 
was also incorporated to assist the escape of 
trapped peptides and improve their cellular 
activity (38). The resultant fusion peptide 
specifically blocked the interaction of S100P 
with immobilised NMIIA (Fig. 6B) and the 
FITC-labelled peptide was taken up by cells 
after an overnight incubation (Fig. 6C). When 
the fusion peptide was pre-incubated with HeLa-
A19 cells for 48 h, cell migration was 
significantly increased by nearly 40% (Fig. 6D). 
This is probably because the peptide also 
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partially overlaps the bundling domain of 
NMIIA (Figs. 2A, 6A)(46). Importantly, 
however, the peptide nearly completely inhibited 
the S100P-enhanced increase in cell migration 
(Fig. 6D). The control peptide containing only 
TAT-HA2 entered cells, but did not significantly 
affect cell migration with or without induction of 
S100P (Fig. 6D). These results support the 
contention that S100P targets NMIIA to enhance 
cell migration.   
Effects of S100P upregulation and NMII 
knockdown on focal adhesion sites (FAS). When  
FAS were located by immunofluorescent staining  
for vinculin and by phalloidin staining actin 
filaments, the majority of actin filaments 
terminated at FAS in the HeLa cells (Figs. 
7A&B). In parental HeLa and non-induced HeLa-
A3 or A19 cells, FAS and actin filaments were 
evenly distributed (Figs. 7A-C) and only 5-10% 
of the fluorescent cells exhibited a peripheral 
distribution of FAS (Supplemental Table 4).  
When S100P was induced for 24 h, the number of 
FAS in the HeLa-A3 and A19 cells was 
significantly reduced by 2-3 fold (P≤0.012,  
Supplemental Table 5) producing a peripheral 
distribution in 40-50% of stained cells (Figs. 
7E&F) (Supplemental Table 4). In parallel, actin 
filaments became more peripherally distributed 
than in HeLa (Fig. 7E&F) or in untreated cells 
(Figs. 7A-C). When NMIIA was knocked down 
in HeLa cells, FAS were reduced by 10-20 fold 
(P=0.001) (Supplemental Table 5), and virtually 
disappeared, but the fewer thicker actin filaments 
were not redistributed to the cellular peripheries 
(Fig. 7G). In contrast, when NMIIB (7H) and IIC 
(7I) were knocked down, there was no obvious 
effect on the average numbers/cell nor 
distribution of either FAS or actin filaments.  
These data suggest that S100P-induced NMIIA 
dissociation caused the redistribution and 
reduction of vinculin-containing and actin-
terminating FAS. 
Inhibition of vinculin production simulates 
S100P enhanced cell migration. Specific  siRNAs 
to vinculin mRNA knocked down its protein level 
by about 80% (Fig.8A) and significantly 
increased HeLa –A19 cell migration by nearly 2-
fold (Fig.8B). However, there was no further 
significant increase in cell migration upon 
induction of S100P (Fig.8B). Control siRNA not 
directed to vinculin mRNA was without any 
effect (Figs.8A, B). The vinculin-containing FAS 
in HeLa-A19 cells after knockdown of vinculin 
also became much less apparent (Fig.8C). These 
data demonstrate that S100P functions via a 
reduction in vinculin and FAS to increase cell 
migration. 
Effects of S100P induction on cell adhesion. 
Both NMIIA filaments and their associated FAS 
are important for cell adhesion (51). The effect of 
S100P on both NMIIA and FAS will be 
eventually reflected by cell adhesion changes.  
When seeded on plastic surfaces the cellular 
adhesion of HeLa cells treated with doxycycline 
was not significantly different from that of 
untreated HeLa cells (Fig. 9A). Once HeLa–A19 
cells were treated with doxycycline to induce 
S100P, cellular adhesion was significantly 
reduced by 30-50% at 60 and 90 min compared to 
that of non-induced HeLa-A19 cells (Student’s t 
test P≤0.02)(Fig. 9B), indicating that induction of 
S100P is able to reduce significantly cell 
adhesion to plastic surfaces in tissue culture. 
Further analysis showed that induction of S100P 
significantly reduced cell adhesion to collagen I 
and II coated surfaces, but not to surfaces coated 
with collagen IV, fibronectin, laminin, tenascin or 
vitronectin (Figs. 9C&D). The reason for the 
differential effects is not clear. 
Inhibition of FAK kinase abolishes the 
stimulatory effect of S100P on cell migration. To 
investigate whether cell migration stimulated by 
S100P in HeLa cells requires activation of focal 
adhesion kinase (FAK), the major kinase for 
assembly and disassembly of FAS (52,53), an 
inhibitor of its phosphorylation, TAE226 (54) 
was added 6 h after plating the cells in a Boyden 
Chamber.  Addition of 0.5 to 5 μM TAE226 
reduced cell migration in a dose-dependent 
manner in HeLa-A3 cells. S100P-enhanced cell 
migration was abolished when TAE226 
concentration exceeded 1 µM (Fig. 10A), at 
which the FAK phosphorylation (Y397) was 
significantly inhibited (Supplemental Fig. 5). 
There was no significant effect on cell 
proliferation in the same time period (Fig. 10B) 
(ANOVA test, P≥0.23). Induction of S100P did 
not change the ratio of pFAK/FAK significantly 
(Supplemental Fig. 5).  When S100P was induced 
in HeLa-A3 cells in the presence of TAE226, 
there was no significant reduction (P=0.11, 
Supplemental Table 6) nor significant peripheral 
redistribution of FAS (P=0.09) (Fig 10C panel F).  
However rearrangement of NMIIA was still 
observed (P=0.01) but in about only half of the 
cells compared to those without TAE226 
(P=0.03)(Fig. 10C, panel C and Supplemental 
Table 6). These results suggest that S100P-
enhanced cell migration requires functional FAK 
kinase and redistribution of FAS.  
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DISCUSSION 
Migration of cancer cells away from the 
primary tumor is the critical initial step in 
metastasis (55,56). We have demonstrated 
previously that both S100A4 and S100P are able 
to promote metastasis in a syngeneic rat model 
for breast cancer and that their overexpression in 
human breast cancer specimens indicate a poor 
patient prognosis (4,7,10). In this work, we 
demonstrate that high levels of S100P are able to 
increase cell migration, both in S100P stably 
transfected and S100P inducible rat and human 
cell lines. Although it has been reported that 
S100A4 and other S100 proteins are associated 
with cell migration (57), this work is the first  to 
establish a direct cause and effect relationship 
between levels of S100P and cell migration 
(linear regression, r=0.93, P=0.035) 
(Supplemental Fig. 3C). 
The driving force for migration in non-muscle 
cells arises mainly from the acto-myosin 
filaments (58).  Non-muscle myosin II (NMII) is 
able to form acto-myosin fibres in non-muscle 
cells and currently three isoforms have been 
identified.    The NMIIA and IIB have opposite 
effects on cell migration with NMIIB serving as 
the driving force, whilst the NMIIA filaments 
serve mainly as a scaffold through which a cell 
adheres, through FAS, to the culture substratum, 
thereby anchoring it. How NMIIB drives cell 
migration is not entirely clear, but its involvement 
in cell polarisation and tail retraction (59) could 
enhance directional movement of cells. In our 
work, we confirm that knockdown of NMIIB 
reduces but knockdown of NMIIA enhances cell 
migration, knockdown of NMIIC shows no 
significant effect. More relevantly, only 
knockdown of NMIIA significantly affects 
S100P-enhanced cell migration, which suggests 
that NMIIA is the major effector of the S100P 
pathway. This point has been confirmed by both 
in vitro and in vivo studies. In vitro, we show 
S100P differentially interacts with the NMII 
isoforms with its highest affinity for NMIIA 
(>NMIIC>>NMIIB). Therefore, S100P mainly 
affects filament formation of NMIIA and NMIIC 
but not NMIIB, similar to that observed with 
S100A4 (12,60-64). With respect to the 
relationship of structure to function, a major site 
identified on NMIIA to which S100P binds in 
vitro (Fig.2A) is contained within a polypeptide 
of NMIIA that, when incorporated into HeLa-
A19 cells, inhibits the ability of S100P to 
stimulate cell migration (Fig.6). In contrast the 
site in the very similar  S100A4 to which NMIIA 
binds is probably not linear, but involves several 
different regions of the S100 molecule (61), all of 
which, when mutated, inhibit its effect in 
stimulating Rama 37 cell migration and 
metastasis (62-64) and results for S100P, at least 
for the C-terminal region are similar (65). 
 In vivo, we demonstrate that S100P is 
partially co-localised with NMII filaments and 
their physical interaction in living cells has been 
confirmed using FRET. The same mutations in 
S100A4 that prevent binding of this molecule to a 
fragment of  NMIIA using an optical  biosensor 
in vitro, also prevent FRET between suitably 
engineered, fluorescent-labelled S100A4 and 
NMIIA in living HeLa cells (64), confirming that 
interaction also does not occur using these 
mutants in vivo. More importantly, we have for 
the first time demonstrated that S100P facilitates 
the dissociation of NMIIA filaments in living 
cells. This point is also supported by the fact that 
the total amount of insoluble NMIIA filaments is 
reduced after S100P induction. In HeLa-A3 or 
A19 cells, the distribution of S100P is more 
central and NMIIA filaments are normally 
distributed more uniformly before rather than 
after induction of S100P. The high levels of 
S100P in the central region induce the 
redistribution of NMIIA filaments to the cellular 
peripheries and thus may weaken their anchoring 
force.  Inhibition of S100P stimulation of 
migration by a specific peptide of NMIIA 
containing the S100P binding region 
demonstrates that interaction between S100P and 
NMIIA is required for this effect in living cells. 
The fact that dissociation of NMIIA filaments 
increases cell migration has also been observed in 
other cell systems.  When blebbistatin is used to 
inhibit NMIIA contraction,  the migration of 
mouse hepatic stellate cells is accelerated (66). 
The S1943A mutation of NMIIA increases its 
ability to form filaments and concomitantly 
reduces migration of MDA-MB 231 cells, while 
the S1943D or S1943E mutation decreases its 
assembly and promotes cell migration (67,68). 
Rho and Rac kinases are profound regulators of 
the cytoskeleton and hence also influence cell 
migration (69). With Rac1, one of the important 
pathways is Rac1/CDC42/PAK (P21-Activated 
Kinase), which causes disassembly of stress 
fibres and FAS, and enhances cell migration (70). 
Another important pathway is Rac1/CDC42 
/IQGAP1, which forms a complex that links the 
actin cytoskeleton and microtubules at the leading 
edges and facilitates cancer cell migration (71).  
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Thus , the Rac1 inhibitor, NSC23766 (72), which 
normally blocks dissociation of acto-myosin IIA 
filaments and FAS (73), inhibits migration of 
S100P- expressing HeLa-A3 cells (Supplemental 
Fig. 6A). Moreover, specific siRNAs to Rac1 
knocked down over 90% of Rac1 protein in 
HeLa-A19 cells and significantly reduce cell 
migration by about 67% and 83%, respectively, 
and to the same basal rate in uninduced and 
S100P-induced cells (Supplemental Figs. 6B,C). 
Rac1 knockdown also caused abundant and 
abnormal NMIIA filaments (Supplemental Fig. 
6D). With Rho activation, integrin clusters are 
aligned through their attachment to the ends of 
stress fibres to form FAS.  Thus inhibition of 
Rho-ROCK activation by Y27623 (74), which 
normally blocks assembly of the acto-myosin IIA 
filaments and FAS formation (75,76), 
significantly increases cell migration in our cell 
systems. Similarly RhoA knockdown in HeLa-
A19 cells by 70% using specific siRNAs reduced 
NMIIA filaments (Supplemental Figs.6C,D) and 
significantly enhanced cell migration by nearly 2-
fold attaining the same rate as in S100P-induced 
cells; there was, however, no further increase in 
specific siRNA-treated S100P-induced cells 
(Supplemental Fig. 6B). These data strongly 
suggest that NMIIA filaments exert an anchoring 
rather than a migratory force. It appears that any 
mechanism that reduces NMIIA assembly, such 
as knockdown using specific siRNA, inhibition of 
Rho kinase and FAK or causes activation of Rac1 
kinase and, as shown here, upregulation of certain 
S100 proteins will eventually facilitate cells to 
migrate away from their current location 
(Supplemental Fig.7) 
In this study, we show that knockdown of 
NMIIA but not NMIIB or IIC dramatically 
reduces the number of vinculin-containing FAS, 
confirming reports in other cell systems (23,77).  
For example, when the contractility of acto-
myosin is reduced by inhibition of myosin light 
chain phosphorylation or by blebbistatin, an 
inhibitor of myosin II, the FAS lose vinculin and 
talin and consequently reduce their adhesion 
forces (51). However, these methods of inhibiting 
contractility of acto-myosin do not change 
adhesion forces in vinculin null cells (51). These 
results suggest that NMIIA exerts its anchoring 
forces through talin and vinculin-containing FAS. 
FAS contains  about 900 identified proteins and 
over half of them respond to the contractility 
changes of acto-myosin (78), indicating the 
fundamental influence of NMIIA on FAS. In our 
cell systems we show that the S100P-induced 
dissociation of NMIIA filaments is another means 
of reducing the number of vinculin-containing 
FAS. 
The FAS is essential for cell adhesion (79). 
Here we show that induction of S100P 
significantly reduces the cell adhesion rates of 
HeLa-A19 cells, especially to surfaces coated 
with collagen I and II. This reduction in adhesion 
is most likely the consequence of the loss of FAS.  
One of the important modulators of the dynamic 
changes of FAS is FAK which also regulates the 
effects of NMIIA contractility on FAS (77,80).  
FAK signalling is critical to FAS turnover, 
therefore once FAS has been assembled, 
inhibition of FAK will prevent the loss of FAS 
(81). In our work, we show that TAE226, an 
inhibitor of FAK, significantly reduces the 
S100P-induced loss of FAS once it is added after 
cells adhere to culture surfaces. As a result, 
S100P-enhanced cell migration is also inhibited. 
Moreover inhibition of vinculin production by 
specific siRNAs both replicates and nullifies the 
stimulatory effect of S100P.  Therefore this 
combined data suggests that S100P-enhanced cell 
migration also requires the disassembly of 
vinculin-containing FAS.  
It is more than a decade since the interaction 
of S100A4 with a major motor protein NMIIA in 
vitro (12,20,82,83) and in vivo (37) has been 
identified, but it was not clear how this 
interaction (21) affects cell migration. Previous 
studies used S100A4 stable expression cells and 
its effects cannot be explicitly demonstrated. 
With the development of S100P-inducible cell 
lines, the dynamic changes of NMIIA filaments 
and associated FAS as well as cellular adhesion 
upon induction of S100P become much more 
obvious than that in stable expression cells and 
have been clearly demonstrated in this study. 
Accordingly, cell migration is much more 
strongly enhanced upon S100P induction than 
that in cells that stably express similar levels of 
S100P. These data suggest that oscillation of 
S100P in cancer cells may be more effective in 
promoting cell migration and metastasis. In 
summary, our new contribution here is the 
establishment of the direct cause-effect 
relationship between overexpression of S100P 
and cell migration as well as the underlying 
mechanism. This novel mechanism consists of a 
signal pathway involving dissociation of NMIIA 
filaments and a consequent weakening of FAS 
anchoring forces coupled with the unopposed 
locomotory action of unaffected NMIIB filaments 
to drive the cells forward. This work lays the 
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basis for why certain S100 proteins cause metastasis in rodent and human cancers.  
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TABLES 
 
Table 1. Kinetics of binding of soluble S100P to immobilised rC-NMII isoforms 
 
a  The S.E. of each determination of kass is derived from the deviation of 4 independent data sets from 
a one-site binding model, calculated by matrix inversion using the FastFit software provided with the 
instrument (Experimental Procedures). No evidence was found for a two-site model of association. 
 b  The correlation coefficient of the linear regression through the kon values used for obtaining kass. 
c  The kdiss is the mean ± S.E. of 7 values, obtained at different concentrations of S100P. No evidence 
was found for a two-site model of dissociation. 
d  The Kd (kinetic) was calculated from the ratio of kdiss/kass, and the S.E. is the combined S.E. of 
the two kinetic parameters. 
e  The Kd  (equilibrium) was calculated from the extent of binding observed at or near equilibrium at 6 
or more different concentrations of S100P in 4 independent experiments. The S.E. is the combined 
error of the 4 experiments. 
 
Immobilised 
Protein 
kass 
(M-1s-1)a 
Mean ± S.E. 
Rb Kdiss 
(s-1)c 
Mean ± S.E. 
Kd  ( nM)d 
(kinetic) 
Mean ± S.E. 
Kd (nM)e 
(equilibrium) 
Mean ± S.E. 
rC-NMIIA 8900 ±2400 0.91-0.98 0.0039±0.0007 430±210 500±200 
rC-NMIIB 990±350 0.94-0.96 0.0078±0.0031 7800±4200 8400±1200 
rC-NMIIC 6800±3300 0.82-0.95 0.0068±0.0016 1000±530 490±100 
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FIGURE LEGENDS 
 
Fig. 1.
 
 Effect of S100P on cell migration.  Representative  examples of the corresponding Western 
blot of S100P and actin from Rama 37 cells (A)  transfected with control vector (lane 1) and S100P 
expression vector (lane 2, pool 1; lane 3, pool 2; lane 4, isolated clone 1 and lane 5, isolated clone 2) 
and from MCF-7 cells (C) transfected with control siRNA (lane 1), S100P specific siRNA-1 and 2 
(lanes 2 and 3) for 48 h. Mean ±SD percentages of corresponding changes of cell migration of 
transfected Rama 37 cells in 24 h (B) or transfected MCF-7 cells in 72 h (D) are shown. *Significantly 
increased in ANOVA test, P<0.01. (E) A representative example of Western blots shows the relative 
levels of S100P after induction of R37-T25, T28 and HeLa-A3, A19 cells with 1 µg/ml of doxycycline 
for 24 h. (F) Mean ±SD percentages of cell migration in 24 h after induction with doxycycline relative 
to those before induction (the control migrations are set at 100%). *Significantly increased in 
Student’s t test p≤ 0.008 when compared before and after doxycycline induction. (G) R37-T25 and 
HeLa -A3 cells were cultured in medium without FCS, but supplemented with 1 mg/ml of bovine 
albumin with or without doxycycline (1 µg/ml) for 48 h. One ml of medium with doxycycline from 
each cell line was collected and freeze dried. S100P was detected by Western blotting. (H) Effect of 
inhibiting RAGE receptor on cell migration of R37-T25 (■) and HeLa-A3 cells (□). Cells were treated 
without (Control) or with 1 µg/ml doxycycline (Doxy), 100 nM rhS100P, 5 µg/ml anti-RAGE 
antibody (R&D, Abingdon, UK) or 500 nM amphoterin-derived peptide (peptide) (Sigma, Gillingham, 
UK). Cell migration of untreated cells (Control) was set to 100%. Doxycycline alone or with anti-
RAGE antibody and amphoterin-derived peptide all significantly increased cell migration, * (Student’s 
t test, P≤0.031 compared to control). Treatments with rhS100P showed no significant differences 
(P≥0.2 compared with controls). Anti-RAGE antibody and amphoterin-derived peptide did not 
significantly reduce S100P-enhanced cell migration (Student’s t test, P≥0.18 compared with doxy 
alone). 
Fig. 2.
 
 Interaction of S100P with NMIIA and its effects on the formation of filaments (A) Amino 
acid sequence alignment of the tail region of the three NMII isoforms; the bundling domain (IIA, 
1855-1903) and a major S100P-binding site (IIA, 1909-1937) are indicated. (B) Diagram of NMIIA 
mutations generated. (C) Gel overlay assay with S100P (upper panel) and S100A4 (middle panel) 
protein to show their interaction with deletion mutants (M1, M2, M3, M4, and M5) and wild type 
(WT) NMIIA C-terminal fragments (Experimental Procedures). Lower panel shows the Coomassie 
blue-stained gel of mutant and wt NMIIA C-terminal fragments used for the gel overlay assay. (D) 
Examples of Western blotting with anti-histag antibody to soluble polyhistidine-tagged NMIIs C-
terminal fragments to demonstrate the effect of different concentrations of S100P on formation of 
NMII filaments in vitro. B=Sample taken before filament formed. The remaining lanes are the same 
volume of samples taken from the supernatants after precipitation of NMII filaments by centrifugation. 
(E) The mean ±SD in arbitrary units of quantified non-filament NMIIs in the supernatant plotted 
against µM of S100P from three independent experiments for IIA (♦ ), IIB (■) and IIC (▲). (F ) 
Bundling buffer containing 0 and 3 µM S100P was used to resuspend the filaments that formed with 0 
S100P as shown in (E). After 40 min incubation, the resuspended filaments were centrifuged and the 
rest of the procedures were the same as those in (D) above. (G) Mean arbitrary units of soluble NMII 
peptides from 3 independent experiments ±SD in (C) above were presented for control (■) and 
addition of 3 µM S100P (□). *Significant increase in Student’s t test, P≤0.007). 
Fig. 3.  Effects of knocking down NMII isoforms and S100P induction on HeLa-A3 cell migration. 
Panels A-C: Effects of knockdown of NMII isoforms on cell migration after induction of S100P. 
HeLa-A3 cells were cultured without (non-induced, S100P was absent) or with (induced, S100P was 
present during siRNA knocking down and migration assay) doxycycline (1 µg/ml) 24 h before 
transfection with: control siRNA (■), specific siRNA-1 (□) or 2 (▨) to knock down NMIIA (A), IIB (B) 
and IIC (C). Cell migration was measured from 48 h to 72 h after transfection. Migration for control 
siRNA transfected cells is set at 100%. *ANOVA test, P<0.05 when compared to HeLa-A3 
transfected with control siRNAs from at least 3 independent experiments. Panels D-F:  Effects of 
induction of S100P on cell migration after knockdown of NMII isoforms.  HeLa-A3 cells were 
cultured in medium without doxycycline for 24 h before transfection with specific siRNA-1 or 2 for 
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NMIIA (D), NMIIB (E) and NMIIC (F) or control siRNA (F). Cell migration was measured from 48 h 
to 72 h after transfection with (□) or without (■) 1 µg/ml doxycycline to induce S100P during 
migration assay. Migration for non-induced cells is set to 100%.  *Significant increase observed in 
Student’s t test P≤ 0.033 between cell migration with and without induction of S100P from at least 3 
independent experiments.  
 
Fig. 4.
 
 Co-localisation and physical interaction of S100P with NMIIA in living cells. (A) Dual 
immunofluorescent staining of MCF-7 cells with anti-S100P (Panels A, C) (green) and anti-NMIIA 
(panels B, C)(red) to demonstrate their co-localisation pattern (C, F). Panels D-F are the enlarged 
images of panels A-C, respectively.  Arrows indicate some nodules where NMIIA and S100P co-
localise.  Bars=20 μm in A-C, and = 10 µm in D-F. (B) Fluorescence lifetime imaging of the 
interaction between S100P and NMIIA. Variations of the fluorescence lifetime distributions found in 
5-7 different HeLa cells co-transfected with wild type ECFP-S100P + NMIIA-EYFP (Panel A) or 
ECFP-S100P + EYFP expression plasmids (B) as a control and their averages are shown in panel C.  
Fig. 5.
 
 Dynamic changes of NMIIA in HeLa-A3 cells upon induction of S100P. (A) HeLa-A3 cells 
were transfected with plasmid to express GFP-NMIIA. After 16 h, doxycycline (1 µg/ml) was added 
to induce S100P, 24 microscopic fields covering about 60 cells with clear fluorescent fibres were 
selected and monitored (Experimental Procedures).  Typical images at 0, 12, 18 and 24 h after addition 
of doxycycline are shown for the same cells. Bar=20 µm. (B) An example of Western blots of Triton-
insoluble NMIIA from HeLa and HeLa-A19 cells with or without doxycycline treatment. Soluble actin 
serves as a loading control. (C) The mean±SD of the relative NMIIA/actin ratios from 3 independent 
experiments are presented by setting the ratio of NMIIA/actin from cells without doxycycline 
treatment as 100%. * Student’s t test P<0.05.  
 Fig.6
 
. Effects of NMIIA peptide on S100P-enhanced cell migration. (A) Amino acid sequence of 
target and control peptides. (B) Biosensor assay. 1 µM S100P was applied to NMIIA biosensor surface 
before (blue) or after blocking with 1 µM NMIIA peptide (green) or control peptide (red). (C) Images 
of HeLa-A19 cells. Target and control peptides were labelled with FITC (Sigma) and incubated with 
HeLa-A19 cells. Cells after 18 h with FITC-target peptides were fixed and stained with Atto-647N-
phalloidin (Sigma). Images were recorded using a LSM5-10 confocal microscope. Both FITC-labelled 
control and NMIIA peptides were taken up by the cells. Only the typical images of FITC-NMIIA 
peptide are shown. Panel A, green dots indicate the FITC-NMIIA peptide taken up by cells and panel 
B, red filaments indicate the acto-myosin fibres, panel C is the transmission image and panel D is the 
superimposed image of A, B and C. (D) Cell migration assay was set up after 24 h incubation without 
(control) or with 5 µM non-labelled peptides in the presence or absence of doxycycline (1 µg/ml). 
Means±SD of relative migration rates to control are presented. * Student’s t test, P<0.05 when 
compared to non-induced  cells with the same treatment. **ANOVA test, P<0.05 when control/S100P-
induced, NMIIA peptide-treated/S100P-induced cells, and control peptide-treated/induced cells are 
compared. ǂANOVA test, P<0.05 when non-induced cells with different treatments are compared. 
Fig. 7.
 
 Dual fluorescent staining of actin filaments and FAS.  HeLa (A, D), HeLa-A3 (B, E) and A19 
cells (C, F) without (A-C, Control) or with (D-F, Doxy) induction of S100P by doxycycline for 24 h 
and HeLa cells with NMII isoforms knocked down using IIA siRNA-1(G), IIB siRNA-2 (H) and IIC 
siRNA-2 (I) were fixed and stained. Typical images of actin filaments (red) labelled by Atto 647N-
Phalloidin (Sigma), FAS (green) located by fluorescently labelled vinculin (anti-vinculin, Sigma), and 
nuclei labelled with DAPI (blue) are shown. All bars=20 µm. 
Fig. 8. Effects of knockdown of vinculin on cell migration. siRNAs specific for vinculin and control 
siRNA from Qiagen were transfected into HeLa-A19 cells. After 48 h, the cell migration assay was set 
up in the presence or absence of doxycycline. The rest of the cells were grown for further 24 h to 
check vinculin protein by Western blotting and immunofluorescent staining using anti-vinculin 
antibody. (A) Typical Western blot. (B) Means±SD of cell migration rates relative to control are 
shown. * Student’s t test, P<0.05 compared between S100P non-induced and induced cells and P=0.61 
compared between vinculin siRNA-treated, uninduced and S100P induced cells. **ANOVA test, 
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P=0.45 when control/S100P-induced, vinculin siRNA-treated/induced, and control siRNA-
treated/induced cells are compared. ǂANOVA test, P<0.05 when uninduced cells with different 
treatments are compared. (C) Typical images of HeLa-A19 cells 72 h after transfection with control 
siRNA (panels A-C) and vinculin siRNA (panels D-F). Green dots indicate vinculin (panels A and D) 
and red fibres indicate NMIIA (panels B and E). Panels C and F are the superimposed images of 
panels A and B, and panels D and E, respectively. Bars = 20 µm. 
 
 Fig. 9. 
 
 Effect of S100P on cell adhesion. HeLa (A) and HeLa-A19 (B) were treated with (□) or 
without (■) doxycycline for 24 hours and cell adhesion assays were carried out as described in 
Experimental Procedures. The percentage of adhesion = 100 x cells retained on the surface of normal 
culture plate (Costar) /total cells seeded. The means±SD from 3 independent experiments were 
presented. The cell adhesion array kit (Millipore) was also used to detect the effect of S100P induction 
on the adhesion of HeLa (C) and HeLa-A19 (D) cells to surfaces coated with different extracellular 
matrix proteins. The cell adhesion without doxycycline treatment (■) was set as 100% and the means 
±SD of relative adhesion after doxycycline treatment (□) are presented. * Student’s t test, P≤0.02.  
Fig. 10.  Effect of FAK kinase inhibitor on cell migration and distribution of FAS. (A) Cell 
migration assay for HeLa –A3 cells with (□) or without (■) doxycycline (1µg/ml) and different 
concentrations of TAE226.  The inhibitor was added 6 h after plating of the cells in the migration 
assay to allow them to adhere.  After a further 18 h incubation, the cells were fixed and stained for 
counting and calculating the migration in 24 h (Experimental Procedures). Results are the mean±SD of 
3 experiments.  *Significant increase in Student’s t test, p≤0.011 when comparing cell migration with 
(□) and without (■) doxycycline. (B)  The inhibitor was added 6 h after 15,000 cells were plated in 
each well of a 24-well culture plate in medium containing 2% (v/v) FCS as in the migration assay. The 
cells were counted after a further 18 h incubation in the absence of doxycycline and the results are the 
mean ± SD of 3 experiments. (C) Dual immunofluorescent staining of NMIIA (red) (panels A-C) and 
FAS (green, vinculin) (panels D-F, same fields as A-C) in HeLa-A3 cells; (panels A, D) untreated 
cells; (panels B, E) cells treated with 1 µg/ml of doxycycline; and (panels C, F) cells treated with 
doxycycline plus 5 µM TAE226. Typical images are shown. All bars=50 µm.  










